Maria-luisa Schubert

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Journal: Bone marrow transplantation
Published: May 20, 2026

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Journal: Blood advances
Published: February 25, 2026

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Journal: Blood advances
Published: February 25, 2026

Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.

Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.

Journal: Transfusion
Published: December 17, 2025

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.

Journal: Bone marrow transplantation
Published: July 27, 2025

Chimeric antigen receptor T-cells for patients with hematologic malignancies

Chimeric antigen receptor T-cells for patients with hematologic malignancies

Journal: Zeitschrift fur Rheumatologie
Published: July 16, 2025

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.

Journal: Nature communications
Published: May 02, 2025

GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis.

GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis.

Journal: Frontiers in immunology
Published: September 22, 2024

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Journal: Leukemia
Published: September 04, 2024

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.

Journal: Leukemia
Published: June 23, 2024

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.

Journal: Blood
Published: May 10, 2024

CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma.

CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma.

Journal: Lancet (London, England)
Published: April 10, 2024
Showing 1-12 of 51

Last Updated: 09/26/2026